ESPERION THERAPEUTICS, INC.
ESPR · NASDAQ
Through scientific and clinical excellence, and a deep understanding of cholesterol biology, the experienced Lipid Management Team at Esperion is committed to developing new LDL-C lowering medicines that will make a substantial impact on reducing global cardiovascular disease, the leading cause of death around the world.
Market Data
Price
$3.18
-0.01 (-0.31%)
Market Cap—
P/E Ratio—
EPS$—
52W High$—
52W Low$—
Beta—
Data from Finnhub · Updated Aug 24, 2026